Company releasesSee allPost date: 06/07/19ALK obtains European approval for its tree SLIT-tablet against allergic rhinitisRead morePost date: 06/04/19As ALK prepares to further extend their SLIT-tablet portfolio, tablet formulation is seen as key in delivering consistent positive clinical trial resultsRead morePost date: 06/03/19Targeted early treatment with ALK’s ACARIZAX® could improve allergic asthma treatment, allergy congress hearsRead morePost date: 05/09/19Three-month interim report (Q1) 2019Read morePost date: 05/02/19Release date of three-month interim report 2019 for ALK and audio castRead morePost date: 03/21/19Grant of share options and performance shares to members of the Board of Management and key employeesRead moreFeatured Events May 9, 2019 Three-month interim report 2019See webcast hereThree-month interim report (Q1) 2019WebcastPresentationQ1-2019Read moreUpcoming Events Aug 13, 2019 Six-month interim report 2019 Nov 7, 2019 Nine-month interim report 2019Read more Annual report 2018 Read more AGM/GeneralforsamlingRead more
